Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNB274
- Development stage
- Preclinical
- Lead developer
- JN Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
JNB274 is a preclinical-stage bifunctional fusion protein developed by JN Biosciences for the treatment of allograft rejection and graft-versus-host disease (GVHD). The molecule consists of an anti-CD122 (IL-2/IL-15 receptor beta subunit) monoclonal antibody fused to the extracellular domain of CTLA4-Ig. This dual-targeting approach is designed to provide synergistic immunosuppression by modulating CD122-expressing effector T cells and natural killer (NK) cells while simultaneously blocking the CD28 costimulatory pathway through the binding of CD80 and CD86 on antigen-presenting cells. By inhibiting both IL-15-mediated survival signals and CD28-mediated activation signals, JNB274 aims to prevent immune-mediated rejection and systemic inflammatory responses in transplant settings.
- Other names
- anti-CD122/CD80/CD86 bifunctional antibody
02
Targets
CD86 (T-lymphocyte activation antigen CD86)CD80 (T-lymphocyte activation antigen CD80)IL2RB (Interleukin-2 receptor subunit beta)
Beyond the preview
Go deeper on JNB274.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNB274.